Subject Index

Activin A
  BMP-4 receptor and, 127
  effects of, 298
  functional and dimeric, 285
All-or-nothing response, 68
Amphibian embryo, induction of erythropoiesis in, 125
Anemia
  aplastic, 101
    severe, EPO levels in, 94
  megaloblastic, 350
Anemia of chronic disorders, inhibitory cytokines in patients with, 344
Anemia of prematurity, 339
Antihormone approaches to cancer therapy, 240
Antisense oligonucleotides, 326, 331
  HOXB genes and, 67
Apoptosis, 268
  erythroid progenitor cells deprived of EPO undergo, 260
Assays, two-site, 109
Autocrine hypothesis, 333

BAF-3 cells, 222
Beta globin, 221
Beta-globin mRNA, accumulation of, 215
BFU-E cells, 324
Birds, immunoreactive EPO in, 366
Blood flow within renal cortex, 76
Bone marrow
  establishment of erythropoiesis in, 271
  total body cell number and, 313
Bone morphogenetic protein-4, 127

Carbon monoxide, 64
Carotid body, arterial PO_2 and, 4
$CD5^+$ B lymphocytes, separate origin of, 141
Cellular oxygen sensors, 3
Central macrophage, EBI consists of, 272
CFU-E cells, 267, 324
Circadian variation, estimates of EPO and, 104
Cis regulatory elements, 25
Cobalt
  EPO production stimulated by, 88
  response to, 64
Cobalt-sensitive response, 47
Cobalt-treated cells, nuclear DNA-binding proteins visualized in, 14
Coelomic cavities, mononuclear cell population in, 144
Colonies, number of, 331
Colony assay, leukemic, 168
Competition between cell lineages, 312, 334
Computer-based model, development of, 203
Consumption, EPO, 350
Contamination, 62
Cortex and medulla, PO_2 in, 77
Cyanide, 66
Cytokines
  inflammatory, 293
  inhibition of EPO production by, 300

Developmental stage of the organism, EPO production by liver and, 50
Differentiation of hematopoietic cells, 213
DNA binding protein, 19
Dose-response curves, 162, 335
Down-regulatory effect, 177

Electrophoretic mobility shift assays, binding of nuclear proteins and, 13
ELISA, accuracy of estimates by, 103
Embryo
  amphibian, 125
  mouse, 140
Embryonic hemopoietic cells, EPO and other cytokines and, 151
Embryonic stem cells, 162
Enhancer, transcriptional, 32
Erythropoietin (EPO)
  G-CSF and, 312
  high levels of, 269, 334
  hypertransfusion-induced inhibitors of, 181
  immunoreactive, in teleosts, amphibians, reptiles, and birds, 366
  intracellular pathways activated by, 223
  nutrition and, 339
  production of erythrocytes controlled by, 259
EPO consumption, 350
EPO gene expression
  inhibition of, by H_2O_2, 341
  location of, in embryo and fetus, 154
  regulatory elements involved in, 13
  tgEPO4 and, 42
EPO levels, circulating, 94
EPO localization, 362
EPO mRNA levels, *in vitro* effects of cytokines on, 300
EPO production, inhibition of, by cytokines, 300
EPO promoter, 39

EPO receptor
  activation of, by a leukemia-inducing retrovirus, 245
  growth-promoting and differentiating-promoting activity of, 213
  human, expression and role of, 232
  life cycle of, 198
  signal transduction and, 185
EPO regulation, inducible response in, 33
EPO therapy, pharmacokinetics and, 111
EPO-hypersecretory state, 85
Epoetin Alfa studies, 111
Erythroblastic island, 272
Erythroid cells, 255
Erythroid genes, retroviral activation of, 245
Erythroid progenitor cell heterogeneity, 262
Erythroleukemias, classical, 246
Erythroleukemic cell lines, 328
Erythropoiesis
  activin A and, 285
  nutrients required for, 260

Ferritin values, 181
Fetal development, 49
Fetal EPO half-time, 182
Fibroblastic reticular cells, 271
Fibronectin, ECM including, 276
Fish, kidney of, 80
Focus-forming virus, 233
Fork head–related transcription factors, 132
Friend virus, 187
Fusion protein, 195

Gastrulation, mesoderm formation and, 147
GATA-1, activation of, by a leukemia-inducing retrovirus, 245
GATA-1–independent regulation, 359
Gel shifts, 18
Gene expression, rapid, high amplitude changes in, 31
Gene-transfer studies in nonerythroid cell lines, 237
Gene-transfer studies in primary hemopoietic cells, 239
Globin gene, 179
Glomus cells, 11
Glycophorin A, 221
Granulocyte colony-stimulating factor, effects of, on erythropoiesis, 312
Granulocyte macrophage colony-stimulating factor receptors, 244

Helices, amphipathic, 202
Hematocrit, 92
Hematopoiesis, knock-out experiments in mice impact on, 178
Hematopoietic growth factor receptors, 214
Heme protein, PCK gene and, 3
Hemopoiesis, definitive, in birds, 145
Hemopoietic homing receptor, 280
Hemopoietic stem cells, maintainable pool of, 140
Hemopoietic system, initiation of, 147
Hep3B and HepG2 cell lines
  cultured liver cells vs, 53
  oxygen-sensing process of, 6
Hep3B cells
  EPO mRNA expression in, 23
  human EPO gene promoter-CAT reporter gene in, 44
Hep3B cultures, 304
Hepatocyte nuclear factor-3, murine, 132
Hepatocytes, liver containing, 52
Hepatoma cell cultures, 301
HepG2 cultures, 303
Heterophilic antibodies, assay invalidity from, 106
HIF-1 complex, 48
HIF-1, site of, 65
Homeobox genes,
  erythroid development and, 155
  role of, in embryogenesis, 165
Homeobox proteins, 179
HOX 2.2, 177
HOX genes, nomenclature for, 165
Humans and mice, 325
Hybridization, *in situ*, 43, 65
Hydrophobic residues, 202
Hypertransfusion-induced inhibitors of erythropoiesis, 181
Hypoxemic rats, EPO production in, 347
Hypoxia
  ATP production under, 4
  changes in gene expression stimulated by, 31
  effect of, 11
  EPO production and, 310
  hematocrit and, 92
  renal, physiology of, 72
  response to, 19
  severe, 40
Hypoxia-inducible enhancer, 50-nucleotide, 44
Hypoxia-inducible factor 1, 45
Hypoxia-inducible transcription, involvement of HIF-1 in, 46
Hypoxia-sensitive response, 47
Hypoxic periods, 61

In situ hybridization, 362
In vitro bioassay, 194

Inhibitors, specificity of, 61
Insulin-like growth factor I, 337
Integrins, 278
Interferon γ, lower hemoglobin levels and, 344
Interferons α and β, 305
Interleukin-1, anemia caused by, 300
Interleukin-3, 221
Internal autocrine concept, 326
Intracellular pathways, EPO-activated, 223
Iron therapy, 181
Isoelectric focusing, 182

Japan, Epoetin Alfa studies in, 111

Kidney
  development and phylogeny of, 150
  high EPO levels in, 310
  hypoxic damage in, 77
  proximal tubular function in, 76
  teleost, 366
  tissue PO_2 within, 74
Kidney cortex, 68
Kidney perfusion, 302
Knock-out experiments in mice, 178

Leukemia, 256
Liver, production of EPO by, 50

Macrophages, mouse peritoneal, 303
Marrow culture, long-term, 285
ME26 virus, 245
Mesoderm
  formation of, gastrulation and, 147
  induction of, 126
Metals, divalent, 56
Microenvironmental differences, 323
Migration, bone marrow and spleen, 316
Minigene constructs, study of regulatory sequences in EPO gene by, 13
Monokines, 310
Mutagenesis, 192
Mutants, 212
Mutations in region of enhancer, 36

Neopterin, lower hemoglobin levels and, 344
Nephrectomy, shift of EPO production from liver to kidneys and, 50
Newborns, 255
Nonparallelism of radioimmunoassay response, 106
Nutrition, EPO and, 339

Oxygen, concentration of, 67
Oxygen sensing, H_2O_2-generating heme proteins and, 341
Oxygen-sensing mechanisms, regulation of EPO production by, 56
Oxygen-sensing system, widespread, 31
Oxygen sensor
  placement of, 78
  proposed model for, 21
Oxygen tension, low, 163
Oxygen tension machinery, 19
Oxygen tensions, intrarenal, 74

P_{50} of oxygen sensor, 11
Para-aortic splanchnopleure, lymphoid progenitors in, 142
Perisinal macrophages, 275
pGEX expression vector, 194
Pharmacokinetics, application of EPO therapy and, 111
Phenylhydrazine, EPO production in response to hypoxemia and, 85
Phorbol myristate acetate, decrease of EPO receptor mRNA levels by, 359
PI 3-kinase, 231
PI 3-kinase activity, 224
Plasmid, 19
PO_2, critical, 75
PO_2 values, 81
PO_2 gradient, 12
Polycythemia
  arterial blood oxygen content and, 83
  tgEPO18 mice and, 42
Polymerase chain reaction, competitive, 302
Posttranscriptional regulation, 23
Potassium channels, cellular oxygen-sensing process influencing, 7
Primary culture, 63
Primary hepatocyte, 64
Primordial germ cell colonies, production of, 154
Progenitor cells, 313
Proliferation, 62
Protein synthesis, 19
Proximal tubules, 347
Pulmonary neuroepithelial bodies, resemblance of, to chemoreceptors, 5–6
Python molurus molurus, serum from, 367

Radioimmunoassay, 198–199
  accuracy of estimates by, 103
Receptor transcript phenotyping, 235

Regulation, transcriptional vs posttranscriptional, 23
Regulatory elements
  Cis, 25
  EPO gene expression and, 13
Renal hypoxia, physiology of, 72
Reticulocyte count and reticulocyte RNA distribution, 353
Reticulocytes, 243
  release of, 283
Retrovirus, *myb-ets*-containing, 245
Rheumatoid arthritis
  EPO levels in, 97
  Epoetin Alpha and, 119

Scanning deletion muteins, 207
Second messengers, rat hepatocytes incubated in presence of, 57
Sequence preservation among mammals, 205
Sialidases, 183
Sialoadhesin, 278
Signal transduction
  differentiation-specific, 215
  EPO receptor and, 185
Site-specific antibodies, 193
Spleen, 325
Spleen cells, total body cell number and, 313
Splenectomized mice, 312
Stem cells, 313
Stochastic model, 331
Stress erythropoiesis, biology of, 83
Stromal cell cultures, 287
Structure-function, 191
Submaxillary salivary glands, assay invalidity and, 105
Subsequences within enhancers, 36
SV40 large T antigen, 356

Teleosts, immunoreactive EPO in, 366
Tertiary structure, 194
Three-dimensional structure of EPO, 203
Thrombospondin, cell attachment and, 277
Transcription factors, erythroid-specific, 165
Transcriptional activation, 20
Transcriptional enhancer, 32
Transcriptional regulation, 23
Transgenic mice, EPO expression in, 41
Tumor necrosis factor, expression of activin A and, 294
Tumor necrosis factor α, anemia caused by, 300
Tyrosine phosphorylations, EPO-induced, 225

UT-7 EPO, 359
UT-7 cells, PI 3-kinase activity and, 226

Virus, 254

Xenopus fork head, 132

Index of Contributors

(Italic page numbers refer to comments made in discussion.)

Acker, H., 3–12, *40*, *64*, *68*, *82*
Adamson, J. W., 359–361
Agmon, Y., 72–82
Alippi, R. M., 83–93, 337–338
Arrizurrieta, E., 347–349
Aurigemma, R. E., 245–256

Barcat, J., 347–349
Barceló, A. C., 83–93, 337–338
Bauer, C., *11*, *19*, *47–48*, *68–69*, 70–71, *82*, *93*, *102*, *109*, *179–180*, *181–184*, *254*, *256*, *269*, *283*, *330–331*, *334–336*
Bechensteen, A. G., 339–340
Beck, I., 13–20
Blanchard, K. L., 21–30
Boissel, J.-P. R., 203–212
Bondurant, M. C., 259–270
Bozzini, C., 83–93
Bozzini, C. E., 83–93, *334*, 337–338, 347–349
Brackmann, I., 147–164
Breymann, C., *181*, *310*, *325*
Brezis, M., 72–82
Bridges, J. M., 191–202
Bunn, H. F., *11*, *18*, 21–30, *62*, *64*, *67–68*, *102*, *139*, *178*, 203–212

Caro, J., 13–20, *39–40*, *48*, *61*, *66–67*, *92*, *101*, *221*, 337–338
Carroll, M., 213–222
Cavill, I., 350–352, 353–355
Clemons, G., *109*, *310*
Conti, M. I., 83–93
Cotes, P. M., *92–93*, 103–110, *182–184*, *269*
Crotta, S., 359–361

D'Andrea, A. D., *48*, *163*, 213–222, *231*, *243–244*, *254–255*, *267–268*, *332*
de Haan, G., 312–325
DeMartino, J., 213–222
Denz, H., 344–346
Dieterlen-Lièvre, F., 140–146, *255*
Doe, B. G., 356–358
Dontje, B., 312–325
Dusanter, I., 223–231

Ebert, B. L., 31–40
Ebrahim, O., 31–40
Eckardt, K.-U., 50–63, *64*, *309*
Elder, G. E., 191–202
Epstein, F. H., *12*, *19*, *48*, *63*, *67*, 72–82, *146*

Fandrey, J., *19*, 21–30, *61*, *67*, 300–311, 341–343
Ferguson, D. J. P., 356–358
Frede, S., 300–311, 341–343
Frid, A., 347–349
Frigon Jr., N. L., 285–299
Fuchs, D., 344–346

Galson, D. L., 21–30
Garcia-Porrero, J. A., 140–146
Gassmann, M., *11*, *162*, *178*
Giglio, M. J., 347–349
Gisselbrecht, S., 223–231
Gobert, S., 223–231
Godin, I. E., 140–146
Goldberg, M. A., 21–30
Goldwasser, E., 1–2, *12*, *19*, *40*, *48*, *61*, *64–67*, *102*, *164*, *177*, *181*, *183*, *201–202*, *212*, *243*, *267*, *298*, 326–333, *334–336*
González, E., 347–349

Hågå, P., 339–340
Halvorsen, S., *181*, 339–340
Hankins, W. D., *19*, *49*, *64*, *67*, *179*, *184*, 232–244, *255–256*, *283*, *324–325*, *332–333*
Hermine, O., 326–333
Heryet, A., 356–358
Hill, C. M., 362–365
Hodges, V. H., 191–202

Jeffries, R., 353–355
Jelkmann, W. E. B., *63*, *66–67*, *81*, *221–222*, 300–311, *334*, 341–343
Jiang, Y., 359–361
Johnson, M. H., 356–358
Johnson, R. A., 165–180

Kelley, L. L., 259–270
Kendall, R. G., 350–352, 353–355
Knöchel, W., 125–139
Koury, M. J., *62*, *66–68*, *93*, *162–163*, *183–184*, *222*, *243–244*, *255*, 259–270, *325*, *331–335*

Kubanek, B., 94–102, *181*, *183–184*, *256*, 257–258, *269*, *310*, *324–325*, *330–331*, *336*
Kurtz, A., 50–63

Lacombe, C., 223–231
Lappin, T. R. J., xi–xiii, 191–202, 362–365
Largman, C., 165–180
Lawrence, H. J., 165–180, *268*
Lezon, C. E., 83–93
Lin, F.-K., *65*, *163–164*, *178*, *182–183*, *202*, *212*, *270*, *299*, *324*, *333*
Loeffler, M., 312–325

Marcos, M. A. R., 140–146
Mathey-Prevot, B., 213–222
Maxwell, P. H., 31–40, 356–358
Mayeux, P., 223–231
McHale, C. M., 191–202
Meier, M., 50–63
Migliaccio, A. R., 359–361, *184*, *221–222*, *244*, *299*
Migliaccio, G., 359–361
Muller, O., 223–231

Nicholls, L. G., 356–358
Nicolis, S., 359–361
Nijhof, W., *65–67*, *268*, *270*, 312–325, *334*
Noé, G., 94–102, 147–164
Norfolk, D. R., 350–352, 353–355

Olivera, M. I., 83–93
Osmond, M. K., 356–358
Ottolenghi, S., 359–361

Pagel, H., 300–311
Pech, N., 326–333
Perrine, S., 165–180
Pharr, P. N., 232–244
Pierce, J. H., 232–244
Pugh, C. W., 31–40, 50–63, 356–358

Ramirez, S., 13–20
Ratcliffe, P. J., 31–40, 50–63, *66–67*, *310*, 356–358
Rich, I. N., xi–xiii, *62*, 94–102, 123–124, 147–164, *284*, *309*, *324*, *331*, *335*
Riedel, W., 147–164
Ronchi, A., 359–361
Ruscetti, S. K., *179*, 232–244, 245–256

Salceda, S., 13–20
Sawyer, S. T., 185–190, *202*, *212*, *231*, 232–244, *332*
Schechter, A. N., 232–244
Schnappauf, U., 147–164
Schrezenmeier, H., 94–102
Semenza, G. L., 41–49, *65–67*, *69*
Shanks, J. H., 362–365
Shao, L.-E., 285–299
Shiels, S., 366–370
Shimosaka, A., 111–122, *182–184*, *256*
Spivak, J. L., 232–244
Stage-Marroquín, B., 326–333

Tan, C. C., 50–63, 356–358
Tavassoli, M., 271–284

Vogt, C., 147–164

Wachter, H., 344–346
Wen, D., 203–212
Wickramasinghe, P. S., 366–370
Wickramasinghe, S. N., 366–370, *254*
Widness, J., *182–183*, *268*
Williams, D. M., 232–244
Wilson, J. G., 271–284
Winter, P. C., 191–202

Yu, A. W., 285–299
Yu, J., 285–299

Zangerle, R., 344–346
Zimmermann, F., 147–164
Zimmers, T. A., 232–244